Advertisement

CardioVasc

, Volume 19, Issue 2, pp 28–33 | Cite as

Atherosklerose und Myokardinfarkt

Inflammation als therapeutisches Target

  • Carina Maria Mauersberger
  • Hendrik B. SagerEmail author
Fortbildung Schwerpunkt Kardiologie
  • 21 Downloads

Inflammatorische Prozesse spielen eine wesentliche Rolle in der Entstehung und Progression kardiovaskulärer Erkrankungen. Nachdem in präklinischen Studien gezeigt wurde, dass Inflammation auch ein therapeutisches Target darstellen kann, wurde in der CANTOS-Studie bei Patienten nach Myokardinfarkt dargelegt, dass eine Reduktion der vaskulären Inflammation die Prognose verbessert.

Literatur

  1. 1.
    Sager HB, Nahrendorf M. Inflammation: a trigger for acute coronary syndrome. Q J Nucl Med Mol Imaging. 2016;60 (3):185-93Google Scholar
  2. 2.
    Sager HB, Kessler T, Schunkert H. Monocytes and macrophages in cardiac injury and repair. J Thorac Dis. 2017;9(Suppl 1):S30–s5CrossRefGoogle Scholar
  3. 3.
    Ruparelia N, Chai JT, Fisher EA, Choudhury RP. Inflammatory processes in cardiovascular disease: a route to targeted therapies. Nat Rev Cardiol. 2016;14(3):133–44.  https://doi.org/10.1038/nrcardio.2016.185CrossRefGoogle Scholar
  4. 4.
    Ridker PM, Everett BM, Thuren T et al. Anti-inflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119–31.  https://doi.org/10.1056/NEJMoa1707914CrossRefGoogle Scholar
  5. 5.
    Ridker PM, MacFadyen JG, Everett BM et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319–28.  https://doi.org/10.1016/s0140-6736(17)32814-3CrossRefGoogle Scholar
  6. 6.
    Ridker PM, Everett BM, Pradhan A et al. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. 2018.  https://doi.org/10.1056/NEJ-Moa1809798Google Scholar
  7. 7.
    Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404–10.  https://doi.org/10.1016/j.jacc.2012.10.027CrossRefGoogle Scholar
  8. 8.
    Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.  https://doi.org/10.1056/NEJ-Moa0807646CrossRefGoogle Scholar
  9. 9.
    White HD, Held C, Stewart R et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014;370(18):1702–11.  https://doi.org/10.1056/NEJMoa1315878CrossRefGoogle Scholar
  10. 10.
    O'Donoghue ML, Braunwald E, White HD et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA. 2014;312(10):1006–15.  https://doi.org/10.1001/jama.2014.11061CrossRefGoogle Scholar
  11. 11.
    Nicholls SJ, Kastelein JJ, Schwartz GG et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA. 2014;311(3):252–62.  https://doi.org/10.1001/jama.2013.282836CrossRefGoogle Scholar
  12. 12.
    Morton AC, Rothman AM, Greenwood JP et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur Heart J. 2015;36(6):377–84.  https://doi.org/10.1093/eurheartj/ehu272CrossRefGoogle Scholar
  13. 13.
    Sager HB, Heidt T, Hulsmans M et al. Targeting Interleukin-1beta Reduces Leukocyte Production After Acute Myocardial Infarction. Circulation. 2015;132(20):1880–90.  https://doi.org/10.1161/CIRCULATIONAHA.115.016160CrossRefGoogle Scholar
  14. 14.
    Everett BM, Cornel J, Lainscak M et al. Anti-Inflammatory Therapy with Canakinumab for the Prevention of Hospitalization for Heart Failure. Circulation. 2018.  https://doi.org/10.1161/CIRCULATIONAHA.118.038010
  15. 15.
    Deftereos S, Giannopoulos G, Angelidis C et al. Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study. Circulation. 2015;132(15):1395–403.  https://doi.org/10.1161/CIRCULATIONAHA.115.017611CrossRefGoogle Scholar
  16. 16.
    O'Donoghue ML, Glaser R, Cavender MA et al. Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial. JAMA. 2016;315(15):1591–9.  https://doi.org/10.1001/jama.2016.3609CrossRefGoogle Scholar
  17. 17.
    Kleveland O, Kunszt G, Bratlie M et al. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. Eur Heart J. 2016;37(30):2406–13.  https://doi.org/10.1093/eurheartj/ehw171CrossRefGoogle Scholar
  18. 18.
    Granger CB, Mahaffey KW, Weaver WD et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation. 2003;108(10):1184–90.  https://doi.org/10.1161/01.CIR.0000087447.12918.85CrossRefGoogle Scholar
  19. 19.
    Armstrong PW, Granger CB, Adams PX et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA. 2007;297(1):43–51.  https://doi.org/10.1001/jama.297.1.43CrossRefGoogle Scholar
  20. 20.
    Tardif JC, Tanguay JF, Wright SR et al. Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. J Am Coll Cardiol. 2013;61(20):2048–55.  https://doi.org/10.1016/j.jacc.2013.03.003CrossRefGoogle Scholar
  21. 21.
    Padfield GJ, Din JN, Koushiappi E et al. Cardiovascular effects of tumour necrosis factor α antagonism in patients with acute myocardial infarction: a first in human study. Heart. 2013;99(18):1330–5CrossRefGoogle Scholar
  22. 22.
    Baran KW, Nguyen M, McKendall GR et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation. 2001;104(23):2778–83CrossRefGoogle Scholar
  23. 23.
    Faxon DP, Gibbons RJ, Chronos NA et al. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. J Am Coll Cardiol. 2002;40(7):1199–204CrossRefGoogle Scholar
  24. 24.
    Moreira DM, Lueneberg ME, da Silva RL et al. MethotrexaTE THerapy in ST-Segment Elevation MYocardial InfarctionS: A Randomized Double-Blind, Placebo-Controlled Trial (TETHYS Trial). J Cardiovasc Pharmacol Ther. 2017;22(6):538–545CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  • Carina Maria Mauersberger
    • 1
  • Hendrik B. Sager
    • 1
    • 2
    Email author
  1. 1.Klinik für Herz- und Kreislauferkrankungen Deutsches Herzzentrum MünchenTechnische Universität MünchenMünchenDeutschland
  2. 2.DZHK (Deutsches Zentrum für Herz-Kreislauf-Forschung e.V.), Partnerseite der Munich Heart AllianceMünchenDeutschland

Personalised recommendations